FTY-720P Suppresses Osteoclast Formation by Regulating Expression of Interleukin-6 (IL-6), Interleukin-4 (IL-4), and Matrix Metalloproteinase 2 (MMP-2)

被引:6
|
作者
Zhang, Dawei [1 ]
Huang, Yongjun [2 ]
Huang, Zongwen [1 ]
Zhang, Rongkai [1 ]
Wang, Honggang [3 ]
Huang, Dong [2 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Orthoped, Sect 2, Zhuhai, Guangdong, Peoples R China
[2] Guangdong 2 Prov Peoples Hosp, Dept Microsurg & Orthoped Trauma, Guangzhou, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Microsurg & Orthoped Trauma, Guangzhou, Guangdong, Peoples R China
来源
MEDICAL SCIENCE MONITOR | 2016年 / 22卷
基金
中国国家自然科学基金;
关键词
Bone Diseases; Interleukin-4; Interleukin-6; Matrix Metalloproteinase 2; Osteoclasts; RELAPSING MULTIPLE-SCLEROSIS; BONE-MARROW; MACROPHAGE LINEAGE; RECEPTOR ACTIVATOR; ORAL FINGOLIMOD; DIFFERENTIATION; RANKL; CELLS; FTY720; GROWTH;
D O I
10.12659/MSM.896690
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Osteoclast formation is closely related to the immune system. FTY720, a new immunosuppressive agent, has some functions in immune regulation. Its main active ingredients become FTY-720P in vivo by phosphorylation modification. The objective of this study was to determine the effects of FTY-720 with various concentrations on osteoclasts in vitro. Material/Methods: RAW264.7 cells and bone marrow-derived mononuclear phagocytes (BMMs) were treated with RANKL to obtain osteoclasts in vitro. To investigate the role of FTY-720 in osteoclast formation, trap enzyme staining was performed and the number of osteoclasts was counted. Bone slices were stained with methylene blue, we counted the number of lacunae after bone slices were placed into dishes together with osteoclasts, and we observed the effect and function of FTY-720 in osteoclasts induced by RAW264.7 cells and BMMs. Then, we used a protein array kit to explore the effects of FTY-720P on osteoclasts. Results: The results of enzyme trap staining and F-actin staining experiments show that, with the increasing concentration of FTY-720P, the number of osteoclast induced by RAW264.7 cells and BMMs gradually decreased (P<0.05), especially when the FTY-720P concentration reached 1000 ng/ml, and the number of osteoclasts formed was the lowest (P<0.05). With bone lacuna toluidine blue staining, the results also show that, with the increasing concentration of FTY-720P, the number of bone lacuna gradually decreased (P<0.05), and the number of lacunae is lowest when the concentration reached 800 ng/ml. Finally, protein array results showed that IL-4, IL-6, IL-12, MMP-2, VEGF-C, GFR, basic FGF, MIP-2, and insulin proteins were regulated after FTY-720P treatment. Conclusions: FTY-720P can suppress osteoclast formation and function, and FTY-720P induces a series of cytokine changes.
引用
收藏
页码:2187 / 2194
页数:8
相关论文
共 50 条
  • [41] A PHASE-I TRIAL OF CONTINUOUS-INFUSION INTERLEUKIN-4 (IL-4) ALONE AND FOLLOWING INTERLEUKIN-2 (IL-2) IN CANCER-PATIENTS
    SOSMAN, JA
    FISHER, SG
    KEFER, C
    FISHER, RI
    ELLIS, TM
    ANNALS OF ONCOLOGY, 1994, 5 (05) : 447 - 452
  • [42] Molecular Cloning and Sequencing of the cDNAs Encoding the Bat Interleukin (IL)-2, IL-4, IL-6, IL40, IL-12p40, and Tumor Necrosis Factor-Alpha
    Iha, Koichiro
    Omatsu, Tsutomu
    Watanabe, Shumpei
    Ueda, Naoya
    Taniguchi, Satoshi
    Fujii, Hikaru
    Ishii, Yoshiyuki
    Kyuwa, Shigeru
    Akashi, Hiroomi
    Yoshikawa, Yasuhiro
    JOURNAL OF VETERINARY MEDICAL SCIENCE, 2009, 71 (12): : 1691 - 1695
  • [43] An asymmetrically dimethylarginated nuclear 90 kDa protein (p90aDMA) induced by interleukin (IL)-2, IL-4 or IL-6 in the tumor microenvironment is selectively degraded by autophagy
    Sun, Lei
    Xia, Wu-Yan
    Zhao, Shao-Hua
    Liu, Ning
    Liu, Shan-Shan
    Xiu, Peng
    Li, Lin-Feng
    Cao, Xue-Lei
    Gao, Jian-Xin
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2016, 48 (06) : 2461 - 2471
  • [44] Expression of an interleukin-6-interleukin-2 fusion protein (pIL-6-IL-2) in P-pastoris
    Yan, L
    Qin, YL
    Bei, WC
    Yu, XL
    Huang, HL
    Chen, HC
    EUROPEAN CYTOKINE NETWORK, 2004, 15 (03) : 240 - 246
  • [45] REGULATORY EFFECT OF INTERLEUKIN-4 (IL-4) ON THE EXPRESSION AND FUNCTION OF LYMPHOCYTE ADHESION RECEPTORS INVOLVED IN IL-2-INDUCED CELL-AGGREGATION
    VYTHDREESE, FA
    VANKOOYK, Y
    DELLEMIJN, TAM
    MELIEF, CJM
    FIGDOR, CG
    IMMUNOLOGY, 1993, 78 (02) : 244 - 251
  • [46] Osteoclast formation from the hemopoietic stem cell line C2GM in response to interleukin-6 (IL-6), soluble IL6-receptor (sIL-6R) and interleukin-11 (IL-11): Dependence on osteoblast density.
    deGrooth, R
    KawilarangdeHaas, EWM
    vandeSandeRijkers, M
    Nijweide, PJ
    JOURNAL OF BONE AND MINERAL RESEARCH, 1996, 11 : S350 - S350
  • [47] Incidence of apoptosis and cell proliferation in multiple myeloma - Correlation with bcl-2 protein expression and serum levels of interleukin-6 (IL-6) and soluble IL-6 receptor
    Chaidos, AI
    Bai, MC
    Kamina, SA
    Kanavaros, PE
    Agnantis, NJ
    Bourantas, KL
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2002, 69 (02) : 90 - 94
  • [48] DEMONSTRATION OF INTERLEUKIN-2, INTERLEUKIN-4, INTERLEUKIN-6 AND SOLUBLE INTERLEUKIN-2 RECEPTOR IN SERA FROM PATIENTS WITH LOCALIZED SCLERODERMA
    IHN, H
    SATO, S
    FUJIMOTO, M
    KIKUCHI, K
    TAKEHARA, K
    ISHIBASHI, Y
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1994, 102 (04) : 584 - 584
  • [49] Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas
    Kossakowska, AE
    Edwards, DR
    Prusinkiewicz, C
    Zhang, MC
    Guo, DL
    Urbanski, SJ
    Grogan, T
    Marquez, LA
    Janowska-Wieczorek, A
    BLOOD, 1999, 94 (06) : 2080 - 2089
  • [50] The role of soluble interleukin (IL)-6 receptor in mediating the effects of IL-6 on matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 expression by gingival fibroblasts
    Irwin, CR
    Myrillas, TT
    Traynor, P
    Leadbetter, N
    Cawston, TE
    JOURNAL OF PERIODONTOLOGY, 2002, 73 (07) : 741 - 747